In this episode we dive deep into new technologies in the ongoing attempt to get cholesterol levels under control worldwide. Heart disease remains the #1 killer in America, and much of the blame falls on high cholesterol. We go into what cholesterol is and some of the new targets and technologies being developed now to help keep the body in line producing the right amount of the right proteins for good cholesterol control.

References:

Occupational Safety and Health Administration. (2025). Accident search results: Keyword “Robot”. U.S. Department of Labor. Accessed 3 September, 2025. https://www.osha.gov/ords/imis/AccidentSearch.search?acc_keyword=%22Robot%22&keyword_list=on&Fatal=fatal

U.S.Centers for Disease Control and Prevention. (2019). Leading causes of death, 1900-1998. U.S. Department of Health and Human Services. https://archive.cdc.gov/www_cdc_gov/nchs/data/dvs/lead1900_98.pdf

Murphy, S. L., Kochanek, K. D., Xu, J., & Arias, E. (2024). Mortality in the United States, 2023. In NCHS Data Briefs [Internet]. National Center for Health Statistics (US). https://www.cdc.gov/nchs/products/databriefs/db521.htm

Makhmudova, U., Steinhagen-Thiessen, E., Volpe, M., & Landmesser, U. (2024). Advances in nucleic acid-targeted therapies for cardiovascular disease prevention. Cardiovascular Research, 120(10), 1107-1125. https://doi.org/10.1093/cvr/cvae136

O'Donoghue, M. L., López, J. A. G., Knusel, B., Gencer, B., Wang, H., Wu, Y., ... & Sabatine, M. S. (2022). Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN (a) reduction-DOSE finding study (OCEAN (a)-DOSE). American Heart Journal, 251, 61-69. https://www.sciencedirect.com/science/article/pii/S0002870322000862

Nissen, S. E., Wolski, K., Cho, L., Nicholls, S. J., Kastelein, J., Leitersdorf, E., ... & Nordestgaard, B. G. (2022). Lipoprotein (a) levels in a global population with established atherosclerotic cardiovascular disease. Open Heart, 9(2), e002060. https://openheart.bmj.com/content/9/2/e002060

Damase, T. R., Sukhovershin, R., Godin, B., Nasir, K., & Cooke, J. P. (2024). Established and emerging nucleic acid therapies for familial hypercholesterolemia. Circulation, 150(9), 724-735. https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.123.067957

Oral, E. A., Garg, A., Tami, J., Huang, E. A., O'Dea, L. S. L., Schmidt, H., ... & Tsimikas, S. (2022). Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study. Journal of Clinical Lipidology, 16(6), 833-849.

Gouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., ... & Yataco, A. (2021). Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The lancet Diabetes & endocrinology, 9(5), 264-275.

Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., ... & Sabatine, M. S. (2024). Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. New England Journal of Medicine, 390(19), 1770-1780.<